Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 18/20 | 1.00 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853555 | 0.97 | APP (0.94) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL12421910 | 0.92 | APP (0.85) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL13806297 | 0.91 | APP (0.84) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL29581521 | 0.89 | APP (0.80) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL5423269 | 0.86 | APP (0.81) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL2194415 | 0.85 | APP (0.72) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL22897342 | 0.84 | APP (0.71) | APPSULT1A1GLAGAAMAPT | |
| SCHEMBL2628263 | 0.84 | APP (1.00) | APPGLAGAAMAPT | |
| SCHEMBL1727124 | 0.84 | APP (1.00) | APPGLAGAAMAPT | |
| SCHEMBL2922465 | 0.83 | APP (0.72) | APPSULT1A1GLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240400549-A1 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | ACADEMIA SINICA (TW) | 2024-12-05 | — | — | US | disclosed |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3841100-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | Arvinas Operations, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112912376-A | Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases | 阿尔维纳斯运营股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| WO-2021075879-A2 | FLUORESCENT PROBE COMPOUND FOR DETECTING PROTEIN AGGREGATES, AND FLUORESCENCE SENSOR FOR DETECTING PROTEIN AGGREGATES, COMPRISING SAME | 고려대학교 산학협력단 | 2021-04-22 | — | — | WO | disclosed |
| CN-111732609-A | Iridium complex with curcumin as ligand and preparation method and application thereof | 青岛农业大学 | 2020-10-02 | — | — | CN | disclosed |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| CN-106496275-A | There is the N of high-affinity with A β plaque block2S22 aryl benzothiazole compound of class and preparation method and application | 北京师范大学 | 2017-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400549-A1 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | HTT, MAPT, GRN | APP 28/4885SULT1A1 4799/4885GLA 131/4885 |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | APP 256/4885SULT1A1 4661/4885GLA 1629/4885 |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | APP 256/4885SULT1A1 4661/4885GLA 1629/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | APP 414/4885SULT1A1 3881/4885GLA 1872/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | APP 256/4885SULT1A1 4661/4885GLA 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.